ELABORATION OF DEFEROXAMINE EMULSION 0.5% FOR HYPERPIGMENTATION DUE TO INTRAVENOUS IRON EXTRAVASATION
3PC-016
PHYSICOCHEMICAL STABILITY OF MOXIFLOXACIN 1 MG/0,2 ML SYRINGES FOR INTRACAMERAL ADMINISTRATION
3PC-015
MICROBIOLOGICAL PERFORMANCE QUALIFICATION OF THE ROBOTIC SYSTEMS APOTECASYRINGE AND APOTECAUNIT
3PC-014
PHYSICOCHEMICAL STABILITY OF BEVACIZUMAB 25 MG/ML CONCENTRATE (VEGZELMA®) IN ORIGINAL GLASS VIALS AFTER FIRST OPENING
3PC-013
RADIOPHARMACEUTICAL SINGLE-VIAL COLD KIT FORMULATION OF FAPI-04, AN EXPERIMENTAL VECTOR FOR GALLIUM-68 PET IMAGING IN ONCOLOGY
3PC-012
CONTENT UNIFORMITY OF SODIUM BENZOATE CAPSULES: VALIDATION OF A METHOD USING QCPREP®
3PC-011
MUCOSECTOMY : FEASIBILITY STUDY OF THE AUTOMATED PREPARATION OF A STERILE SOLUTION OF 5/10% FRUCTOSE GLYCEROL.
3PC-010
DEVELOPMENT OF A STABLE PARENTERAL SOLUTION OF TOPIRAMATE FOR EMERGENCY TREATMENT OF STATUS EPILEPTICUS
3PC-009
THE EFFECT OF ACCELERATED LIGHT (STRESS) AND NATURAL SUNLIGHT EXPOSURES ON CETUXIMAB (ERBITUX®): EVALUATION OF AGGREGATE FORMATION AND FUNCTIONALITY
3PC-008
STABILITY OF PARENTERAL NUTRITION ADMIXTURES: FOCUS ON PRECIPITATION.
3PC-007
CONTAINMENT PERFORMANCE ASSESSMENT OF CHEMFORT® (ONGUARD®2) CLOSED SYSTEM TRANSFER DEVICE ACCORDING TO 2016 DRAFT NIOSH PROTOCOL AT FIRST AND TENTH ACTIVATIONS END OF SHELF LIFE.
3PC-006
STABILITY STUDY OF CLOBAZAM LIQUID ORAL FORMS FOR PEDIATRIC PATIENTS
3PC-005
PREPARATION OF EPICUTANEOUS TESTS WITH MINOXIDIL AT 2% AND 5%.
3PC-004
DRUG WASTE OF READY-TO-ADMINISTER SYRINGES IN THE INTENSIVE CARE UNIT: ASEPTICALLY PREPARED SYRINGES VERSUS PREFILLED STERILISED SRYINGES
